Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Approves Eisai MDS Drug Dacogen Five-day Dosing Regimen

This article was originally published in PharmAsia News

Executive Summary

Eisai obtained U.S. FDA approval for five-day dosing of Dacogen (decitabine) injection for patients with myelodysplastic syndromes. The new regimen will be administered at a dose of 20 mg continuous intravenous injection over one hour repeated daily for five days per cycle. The cycle is repeated every four weeks. Currently, Dacogen's three-day regimen is administered in an in-patient setting at a dose of 15 mg IV injection over three hours repeated every eight hours for three days per cycle and repeated every six weeks. Eisai hopes the shortened administration time and out patient convenience will increase the number of patients. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC074354

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel